All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results ConPlas-19, 2020 0.56 [0.20; 1.57]
DAWN-Plasma, 2021 0.61 [0.24; 1.55]
NCT04397757, 2021 0.47 [0.04; 5.45]
Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
0.82 [0.42 ; 1.61 ] ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021 4 24% 1,072 moderate not evaluable death D28detailed results AlQahtani, 2020 0.47 [0.04; 5.69]
ASCOT, 2021 0.60 [0.06; 5.99]
Balcells, 2020 4.22 [0.33; 53.77]
Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
CONCOR-1, 2021 1.12 [0.86; 1.46]
ConPlas-19, 2020 0.49 [0.20; 1.19]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
ITAC, 2022 0.80 [0.42; 1.52]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kirenga, 2021 1.25 [0.46; 3.39]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Menichetti, 2021 0.75 [0.37; 1.53]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04528368, 2021 0.88 [0.02; 50.20]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
Tabarsi, 2020 1.10 [0.45; 2.67]
0.91 [0.83 ; 0.99 ] AlQahtani, 2020, ASCOT, 2021, Balcells, 2020, Bennett-Guerrero, 2021, Co-CLARITY, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COPLA-II trial, 2020, DAWN-Plasma, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Kirenga, 2021, Li, 2020, LIFESAVER, 2021, Menichetti, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04528368, 2021, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Tabarsi, 2020 34 9% 23,129 moderate critical death or transfer to ICUdetailed results Lopardo, 2021 0.65 [0.35; 1.22]
0.65 [0.35 ; 1.22 ] Lopardo, 2021 1 0% 241 NA not evaluable deathsdetailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
AlQahtani, 2020 0.47 [0.04; 5.69]
ASCOT, 2021 0.60 [0.06; 5.99]
Balcells, 2020 3.26 [0.62; 17.12]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CAPSID, 2021 0.84 [0.28; 2.50]
CCAP-2, 2021 2.03 [0.61; 6.77]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59]
CONFIDENT, 2020 0.84 [0.52; 1.37]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COP-COVID-19, 2021 0.96 [0.36; 2.56]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Darazam, 2021 1.21 [0.65; 2.25]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Fu, 2020 1.00 [0.02; 51.66]
Holm K, 2021 0.49 [0.08; 2.89]
ITAC, 2022 0.80 [0.42; 1.52]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kirenga, 2021 1.25 [0.46; 3.39]
Li, 2020 0.59 [0.22; 1.59]
Li, 2021 1.04 [0.02; 53.73]
Libster, 2020 0.50 [0.09; 2.71]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Lopardo, 2021 0.57 [0.24; 1.37]
Menichetti, 2021 0.75 [0.37; 1.53]
NCT04385199, 2021 0.75 [0.15; 3.77]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04442191, 2021 0.11 [0.00; 143.68]
NCT04528368, 2021 0.88 [0.02; 50.20]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
Rasheed, 2020 0.13 [0.01; 1.09]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
Tabarsi, 2020 1.10 [0.45; 2.67]
Wang, 2020 1.00 [0.02; 52.54]
0.92 [0.86 ; 0.99 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, AlQahtani, 2020, ASCOT, 2021, Balcells, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CAPSID, 2021, CCAP-2, 2021, Co-CLARITY, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COP-COVID-19, 2021, COPLA-II trial, 2020, CP-COVID-19, 2021, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DAWN-Plasma, 2021, Fu, 2020, Holm K, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Kirenga, 2021, Li, 2020, Li, 2021, Libster, 2020, LIFESAVER, 2021, Lopardo, 2021, Menichetti, 2021, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04442191, 2021, NCT04528368, 2021, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Rasheed, 2020, RECOVER, 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, REMAP-CAP (plasma), 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, SOLIDARITY (interferon), 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020, Tabarsi, 2020, Wang, 2020 60 7% 33,413 moderate critical deaths (time to event analysis only)detailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
Balcells, 2020 3.26 [0.62; 17.12]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
PlasmAr, 2020 0.93 [0.47; 1.85]
0.94 [0.75 ; 1.17 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, Balcells, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, Kalil (ACTT-3), 2021, PlasmAr, 2020 11 17% 5,250 moderate low clinical deteriorationdetailed results Balcells, 2020 1.46 [0.44; 4.81]
CAPSID, 2021 0.63 [0.29; 1.40]
ConPlas-19, 2020 1.00 [0.65; 1.53]
CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
Kirenga, 2021 0.91 [0.38; 2.17]
Li, 2021 0.52 [0.02; 15.78]
Libster, 2020 0.52 [0.29; 0.94]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
Wang, 2020 1.00 [0.02; 52.54]
0.87 [0.73 ; 1.04 ] Balcells, 2020, CAPSID, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, Kirenga, 2021, Li, 2021, Libster, 2020, Synairgen SG016, 2020, Wang, 2020 9 0% 1,658 moderate not evaluable clinical improvementdetailed results ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
Balcells, 2020 0.91 [0.52; 1.60]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
CAPSID, 2021 1.58 [0.71; 3.49]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam, 2021 1.37 [0.88; 2.13]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
ITAC, 2022 1.06 [0.77; 1.45]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Li, 2020 1.40 [0.79; 2.49]
Li, 2021 1.76 [1.10; 2.81]
Lopardo, 2021 1.61 [0.75; 3.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
1.12 [1.00 ; 1.25 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, Balcells, 2020, Bennett-Guerrero, 2021, CAPSID, 2021, ConPlas-19, 2020, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Li, 2020, Li, 2021, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Synairgen SG016, 2020 19 39% 5,269 moderate critical clinical improvement (14-day)detailed results Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Li, 2020 2.27 [0.90; 5.72]
Li, 2021 2.86 [1.24; 6.62]
Pandit, 2021 8.77 [0.94; 81.67]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
1.64 [0.85 ; 3.16 ] Kalil (ACTT-3), 2021, Li, 2020, Li, 2021, Pandit, 2021, Shashi Bhushan, 2021 5 66% 1,447 moderate not evaluable clinical improvement (28-day)detailed results Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
Li, 2020 1.42 [0.65; 3.10]
Li, 2021 4.26 [1.10; 16.44]
O’Donnell, 2021 1.38 [0.73; 2.61]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
1.78 [1.06 ; 3.00 ] Bennett-Guerrero, 2021, Li, 2020, Li, 2021, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Synairgen SG016, 2020 7 68% 815 moderate serious clinical improvement (7-day)detailed results ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ITAC, 2022 1.06 [0.77; 1.45]
Li, 2020 0.98 [0.27; 3.58]
Li, 2021 1.83 [0.41; 8.14]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
1.11 [0.84 ; 1.48 ] ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022, Li, 2020, Li, 2021, Shashi Bhushan, 2021 5 21% 1,318 moderate not evaluable clinical improvement (time to event analysis only)detailed results Balcells, 2020 0.91 [0.52; 1.60]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam, 2021 1.37 [0.88; 2.13]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Li, 2020 1.40 [0.79; 2.49]
Li, 2021 1.76 [1.10; 2.81]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Rahmani, 2020 3.41 [1.33; 8.73]
1.21 [1.02 ; 1.43 ] Balcells, 2020, Bennett-Guerrero, 2021, ConPlas-19, 2020, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Kalil (ACTT-3), 2021, Li, 2020, Li, 2021, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020 12 44% 2,252 moderate critical death or ventilationdetailed results Balcells, 2020 0.67 [0.14; 3.26]
CONCOR-1, 2021 1.16 [0.94; 1.43]
ConPlas-19, 2020 0.94 [0.86; 1.02]
DAWN-Plasma, 2021 1.01 [0.64; 1.59]
Menichetti, 2021 0.88 [0.59; 1.32]
RECOVERY (plasma), 2021 0.99 [0.93; 1.05]
RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92]
SOLIDARITY (interferon), 2020 1.05 [0.90; 1.23]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
0.94 [0.87 ; 1.03 ] Balcells, 2020, CONCOR-1, 2021, ConPlas-19, 2020, DAWN-Plasma, 2021, Menichetti, 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, SOLIDARITY (interferon), 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020 10 54% 21,620 moderate low hospital dischargedetailed results ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
ConPlas-19, 2020 1.02 [0.82; 1.28]
DAWN-Plasma, 2021 1.06 [0.87; 1.30]
Rahmani, 2020 3.44 [0.64; 18.49]
RECOVERY (plasma), 2021 0.99 [0.92; 1.07]
RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
1.09 [0.98 ; 1.21 ] ACTIV-3/TICO LY-CoV555 , 2020, ConPlas-19, 2020, DAWN-Plasma, 2021, Rahmani, 2020, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020 8 55% 17,222 moderate not evaluable hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results AlQahtani, 2020 0.67 [0.22; 2.02]
Balcells, 2020 2.98 [0.41; 21.61]
COPLA-II trial, 2020 0.58 [0.37; 0.92]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Holm K, 2021 0.39 [0.01; 12.68]
Li, 2021 0.52 [0.02; 15.78]
NCT04397757, 2021 0.41 [0.13; 1.35]
O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
Rahmani, 2020 0.29 [0.05; 1.56]
RECOVERY (plasma), 2021 0.98 [0.88; 1.09]
Sakoulas, 2020 0.19 [0.03; 1.11]
Tabarsi, 2020 1.49 [0.59; 3.78]
0.85 [0.67 ; 1.07 ] AlQahtani, 2020, Balcells, 2020, COPLA-II trial, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Holm K, 2021, Li, 2021, NCT04397757, 2021, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, RECOVERY (plasma), 2021, Sakoulas, 2020, Tabarsi, 2020 14 15% 12,405 moderate low mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
DAWN-Plasma, 2021 1.08 [0.65; 1.80]
0.97 [0.62 ; 1.52 ] CP-COVID-19, 2021, DAWN-Plasma, 2021 2 0% 583 moderate not evaluable radiologic improvement (14-day)detailed results Tabarsi, 2020 2.33 [0.45; 12.00]
2.33 [0.45 ; 12.00 ] Tabarsi, 2020 1 0% 84 NA not evaluable viral clearance detailed results Balcells, 2020 2.66 [0.69; 10.20]
CP-COVID-19, 2021 1.12 [0.16; 7.84]
Jagannathan, 2020 0.81 [0.56; 1.18]
Li, 2021 7.68 [0.91; 65.15]
Pandit, 2021 2.33 [0.55; 9.83]
Raman, 2021 36.42 [10.85; 122.18]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
3.00 [1.12 ; 8.03 ] Balcells, 2020, CP-COVID-19, 2021, Jagannathan, 2020, Li, 2021, Pandit, 2021, Raman, 2021, Salman, 2020, Shashi Bhushan, 2021 8 84% 772 moderate not evaluable viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
Li, 2021 1.74 [1.10; 2.75]
1.17 [0.56 ; 2.48 ] Jagannathan, 2020, Li, 2021 2 84% 216 moderate not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 1.51 [0.33; 6.94]
Kirenga, 2021 0.95 [0.76; 1.19]
Li, 2021 1.74 [0.71; 4.29]
Pandit, 2021 10.23 [1.12; 93.35]
Raman, 2021 36.42 [10.85; 122.18]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
1.15 [0.15 ; 9.03 ] CP-COVID-19, 2021, Kirenga, 2021, Li, 2021, Pandit, 2021, Raman, 2021, Shashi Bhushan, 2021 6 97% 1,778 moderate not evaluable viral clearance by day 7detailed results Balcells, 2020 2.66 [0.69; 10.20]
Kirenga, 2021 0.87 [0.65; 1.16]
Li, 2021 2.20 [0.95; 5.10]
Pandit, 2021 2.33 [0.55; 9.83]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.79 [0.95 ; 3.39 ] Balcells, 2020, Kirenga, 2021, Li, 2021, Pandit, 2021, Salman, 2020, Shashi Bhushan, 2021 6 67% 580 moderate not evaluable ICU admissiondetailed results CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Libster, 2020 0.33 [0.07; 1.58]
Lopardo, 2021 0.67 [0.35; 1.28]
Rahmani, 2020 0.37 [0.14; 1.00]
Tabarsi, 2020 0.56 [0.18; 1.74]
0.60 [0.41 ; 0.88 ] CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Libster, 2020, Lopardo, 2021, Rahmani, 2020, Tabarsi, 2020 7 0% 731 moderate not evaluable recoverydetailed results ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
Synairgen SG016, 2020 2.19 [1.03; 4.67]
1.12 [0.97 ; 1.28 ] ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, Synairgen SG016, 2020 4 7% 1,129 low not evaluable composite safety outcome detailed results ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable related SAE (TRSAE)detailed results Wang, 2020 2.04 [0.07; 63.93]
2.04 [0.07 ; 63.93 ] Wang, 2020 1 0% 48 NA not evaluable serious adverse eventsdetailed results Balcells, 2020 4.54 [0.20; 105.23]
CONCOR-1, 2021 1.27 [1.02; 1.58]
ConPlas-19, 2020 0.89 [0.43; 1.86]
ITAC, 2022 0.98 [0.66; 1.46]
Jagannathan, 2020 1.00 [0.14; 7.34]
O’Donnell, 2021 0.64 [0.35; 1.17]
Pandit, 2021 0.95 [0.02; 50.33]
PlasmAr, 2020 1.40 [0.78; 2.51]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
1.16 [0.99 ; 1.36 ] Balcells, 2020, CONCOR-1, 2021, ConPlas-19, 2020, ITAC, 2022, Jagannathan, 2020, O’Donnell, 2021, Pandit, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021 11 8% 4,860 moderate low superinfectiondetailed results Rahmani, 2020 0.18 [0.02; 1.59]
0.18 [0.02 ; 1.59 ] Rahmani, 2020 1 0% 66 NA not evaluable adverse eventsdetailed results Jagannathan, 2020 1.33 [0.63; 2.78]
Kirenga, 2021 1.13 [0.50; 2.58]
Pandit, 2021 1.68 [0.47; 5.97]
Raman, 2021 1.36 [0.56; 3.30]
Sakoulas, 2020 1.00 [0.02; 53.46]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Wang, 2020 3.57 [0.93; 13.72]
1.16 [0.94 ; 1.43 ] Jagannathan, 2020, Kirenga, 2021, Pandit, 2021, Raman, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Wang, 2020 7 0% 637 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-11 10:20 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290